Monitor the special meeting of shareholders to approve the merger, regulatory clearance, and any competing bids. The $3.16/share cash offer provides a floor, but deal risks include shareholder vote and antitrust review. CVR milestones depend on future net sales performance.
ESPR drugs
ESPR drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · May 4 $3.12entry
- T+1 · 7mo ago 0.00%α −0.80% · $3.12
- T+5 · 6mo ago +0.32%α −2.62% · $3.13
- T+20 · 6mo ago +0.32%α −5.32% · $3.13
- T+60 · due 4mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Esperion Therapeutics entered into a definitive agreement to be acquired by ARCHIMED for $3.16 per share in cash, plus contingent milestone payments of up to $100 million tied to future net sales performance. The transaction is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals.
Key Financial Metrics
Key Facts
- Acquisition price of $3.16 per share in cash
- Contingent milestone payments of up to $100 million in aggregate
- Expected closing in Q3 2026
- Agreement and Plan of Merger dated May 1, 2026
- Acquirer is ARCHIMED, a healthcare-focused investment firm
Financial Impact
Acquisition values equity at approximately $515M based on current market cap; plus up to $100M in contingent value rights
Risk Factors
- Shareholder may vote against the merger
- Regulatory approvals may not be obtained
- Contingent milestone payments may not materialize
- Potential competing bids or go-shop period (if any)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-054100 |
| Document: 0001104659-26-054100-index-headers.html | 0001104659-26-054100 |
| Document: 0001104659-26-054100-index.html | 0001104659-26-054100 |
| Document: 0001104659-26-054100.txt | 0001104659-26-054100 |
Track record
21 reports on ESPR
3 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
- Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
- Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
- Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
- Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers